Mette Pernille Myklebust1, Anne Mette Søviknes2, Ole Johan Halvorsen3, Anna Thor4, Olav Dahl5,6, Helge Ræder2,7. 1. Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway; mette.pernille.myklebust@helse-bergen.no. 2. Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway. 3. Gade Laboratory for Pathology, Department of Clinical Medicine, Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway. 4. Department of Urology and CLINTEC Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. 5. Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway. 6. Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway. 7. Department of Pediatrics, Haukeland University Hospital, Bergen, Norway.
Abstract
BACKGROUND: Testicular germ cell tumours (TGCTs) are the most frequent tumour type among young, adult men. TGCTs can be efficiently treated, but metastases of the teratoma subtype, for which there are no circulating biomarkers, represent a challenge. MATERIALS AND METHODS: Global microRNA expression in teratoma tissue and embryoid bodies was assessed using next-generation sequencing. Levels of microRNAs identified as potential biomarkers were obtained from serum of patients with teratoma and matched healthy men. RESULTS: We identified miR-222-5p, miR-200a-5p, miR-196b-3p and miR-454-5p as biomarker candidates from the tumour tissue and embryoid body screening but the expression of these microRNAs was very low in serum and not statistically different between patients and controls. miR-375-3p was highly expressed, being highest in patients with teratoma (p=0.012) but the levels of expression in serum from these patients and healthy controls overlapped. miR-371a-3p was not expressed in serum from patients with pure teratoma, only in patients with mixed tumours. CONCLUSION: The microRNA profiles of the teratoma subtype of TGCT and embryoid bodies were obtained and assessed for candidate circulating biomarkers, but none with high sensitivity and specificity for teratoma were identified in our study. We conclude that neither the proposed teratoma marker miR-375-3p nor miR-371a-3p are suitable as circulating teratoma markers.
BACKGROUND: Testicular germ cell tumours (TGCTs) are the most frequent tumour type among young, adult men. TGCTs can be efficiently treated, but metastases of the teratoma subtype, for which there are no circulating biomarkers, represent a challenge. MATERIALS AND METHODS: Global microRNA expression in teratoma tissue and embryoid bodies was assessed using next-generation sequencing. Levels of microRNAs identified as potential biomarkers were obtained from serum of patients with teratoma and matched healthy men. RESULTS: We identified miR-222-5p, miR-200a-5p, miR-196b-3p and miR-454-5p as biomarker candidates from the tumour tissue and embryoid body screening but the expression of these microRNAs was very low in serum and not statistically different between patients and controls. miR-375-3p was highly expressed, being highest in patients with teratoma (p=0.012) but the levels of expression in serum from these patients and healthy controls overlapped. miR-371a-3p was not expressed in serum from patients with pure teratoma, only in patients with mixed tumours. CONCLUSION: The microRNA profiles of the teratoma subtype of TGCT and embryoid bodies were obtained and assessed for candidate circulating biomarkers, but none with high sensitivity and specificity for teratoma were identified in our study. We conclude that neither the proposed teratoma marker miR-375-3p nor miR-371a-3p are suitable as circulating teratoma markers.
Authors: Kitchener D Wilson; Shivkumar Venkatasubrahmanyam; Fangjun Jia; Ning Sun; Atul J Butte; Joseph C Wu Journal: Stem Cells Dev Date: 2009-06 Impact factor: 3.272
Authors: Mark H Chin; Mike J Mason; Wei Xie; Stefano Volinia; Mike Singer; Cory Peterson; Gayane Ambartsumyan; Otaren Aimiuwu; Laura Richter; Jin Zhang; Ivan Khvorostov; Vanessa Ott; Michael Grunstein; Neta Lavon; Nissim Benvenisty; Carlo M Croce; Amander T Clark; Tim Baxter; April D Pyle; Mike A Teitell; Matteo Pelegrini; Kathrin Plath; William E Lowry Journal: Cell Stem Cell Date: 2009-07-02 Impact factor: 24.633
Authors: Eric C Umbreit; Bilal A Siddiqui; Michael J Hwang; Aron Y Joon; Tapati Maity; Mary E Westerman; Kelly W Merriman; Hussam Alhasson; Joma Uthup; Tao Guo; Joseph A Moore; John F Ward; Jose A Karam; Christopher G Wood; Louis L Pisters; Miao Zhang; Shi-Ming Tu Journal: Cancers (Basel) Date: 2020-12-14 Impact factor: 6.639
Authors: Yngvild Bjørlykke; Anne M Søviknes; Laurence Hoareau; Heidrun Vethe; Andreas F Mathisen; Simona Chera; Marc Vaudel; Luiza M Ghila; Helge Ræder Journal: Stem Cells Int Date: 2019-11-18 Impact factor: 5.443